Provided by Tiger Trade Technology Pte. Ltd.

AbCellera Biologics

14.59
-0.2300-1.55%
Pre-market: 14.680.0862+0.59%04:12 EDT
Volume:4.86M
Turnover:72.03M
Market Cap:4.73B
PE:-26.74
High:15.02
Open:14.78
Low:14.56
Close:14.82
52wk High:15.02
52wk Low:2.75
Shares:324.00M
Float Shares:221.00M
Volume Ratio:0.83
T/O Rate:2.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5455
EPS(LYR):-0.4902
ROE:-17.30%
ROA:-10.39%
PB:5.28
PE(LYR):-29.77

Loading ...

Abcellera to Announce Top-Line Results from the Phase 2 Trial of Abcl635 for the Treatment of Moderate-to-Severe Vms Due to Menopause on Monday, August 10, 2026

THOMSON REUTERS
·
Aug 08

Piper Sandler Remains a Buy on AbCellera Biologics (ABCL)

TIPRANKS
·
Aug 07

AbCellera Biologics (ABCL) Stock Jumps As Cash Burn Fuels Pipeline Debate

Simply Wall St.
·
Aug 07

OmniAb Q2 Revenue Beats Analyst Estimates, Outlook Raised

Reuters
·
Aug 07

AbCellera Biologics is Maintained at Buy by Stifel

Dow Jones
·
Aug 06

AbCellera Biologics (ABCL) Gets a Buy from Cantor Fitzgerald

TIPRANKS
·
Aug 06

AbCellera Biologics Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

AbCellera Q2 FY26 Net Loss Widens to USD 55.4 Million; Revenue Drops to USD 4.1 Million

Reuters
·
Aug 06

AbCellera Biologics Q2 EPS $(0.18) Misses $(0.14) Estimate, Sales $4.050M Miss $7.784M Estimate

Benzinga Earnings
·
Aug 06

AbCellera Q2 Revenue USD 4.1 Million Vs. IBES Estimate USD 7.78 Million

Reuters
·
Aug 06

Press Release: AbCellera Reports Q2 2026 Business Results

Dow Jones
·
Aug 06

Abcellera Biologics Inc Expected to Post a Loss of 14 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Earning Preview: AbCellera Biologics Q2 revenue is expected to increase by 27.21%, and institutional views are cautiously positive

Earnings Agent
·
Jul 30

AbCellera Partners with Vertex to Develop Multispecific T-cell Engagers for Autoimmune Diseases, Other Conditions

Reuters
·
Jul 29

Abcellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

THOMSON REUTERS
·
Jul 29

Abcellera Biologics - Vertex to Fund All R&D and Commercialize Antibodies from Collaboration

THOMSON REUTERS
·
Jul 29

Abcellera Biologics - Abccellera to Receive $28 Mln Upfront Plus Milestone Payments and Tiered Royalties

THOMSON REUTERS
·
Jul 29

Does AbCellera’s New Board Appointment Reframe Its Execution Story for Investors in ABCL?

Simply Wall St.
·
Jul 20

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), AbCellera Biologics (ABCL) and DBV Technologies SA – American (DBVT)

TIPRANKS
·
Jul 17

Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS) and AbCellera Biologics (ABCL)

TIPRANKS
·
Jul 16